-
A Study About Gene Therapy for Early Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)
Official Title A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of AAV2-BDNF [Adeno-Associated Virus (AAV)-based, Vector-Mediated Delivery of Human Brain Derived Neurotrophic Factor] in Subjects with Early Alzheimer’s Disease and Mild Cognitive ImpairmentPurpose
The primary aim of this study is to determine whether administration of the nervous system growth factor "Brain-Deruved Neurotrophic Factor" (BDNF) to eligible patients with Alzheimer's disease and Mild Cognitive Impairment is safe and tolerable. This study will be used to determine whether BDNF administration reduces neuronal loss and rebuilds synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).
Could this study be right for you?
- Male and Females aged 50 years or older
- Diagnosis of dementia due to Alzheimer's Disease/Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease
- A caregiver is available who has frequent contact with the subject, agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol
- CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal
Inclusion Criteria varies, please contact Study Coordinator for more information.
The below Exclusion Criteria apply to both the AD and MCI groups.
- Any significant neurological disease other than suspected incipient disease
- History of schizophrenia
- History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
- Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol
- Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to screening.
Exclusion Criteria varies, please contact Study Coordinator for more information.
Age Range
50 and up -
An Observational Study to Examine School Transition after Traumatic Brain Injury
Official Title STATBI: School Transitions after Traumatic Brain InjuryPurpose
The purpose of this study is to understand the best ways to help students return to school after brain injury of any severity. This is important to study because finding the best ways to help students go back to school right after brain injury, and over time, can help improve student success and recovery.
Your participation in the study would take place when you/your child begins the study and then at 3 months, 6 months, 12 months, 2 years (if applicable) and 3 years (if applicable) after the study starts.
Could this study be right for you?
- Students aged 5 to 18 years old
- In kindergarten through 12th grade
- Must Speak English
- Traumatic Brain Injury (TBI) of any severity
- Parent/caregiver is willing to share medical and academic information with the research team (all study activities are virtual/remote)
Age Range
5 and up -
A Study about Fitness, Aging, and Stress in People with Traumatic Brain Injury
Official Title Fitness, Aging, Stress & TBI Exposure Repository (FASTER)Purpose
The purpose of this study is to examine how individual differences in health changes (muscle strength, blood pressure) and behavioral changes (sleep, physical activity) impact memory, attention, and the brain. We study these relationships among a variety of older adults, including those with a history of concussion, traumatic brain injury (TBI), and posttraumatic stress disorder (PTSD). The long-term goal of this project is to identify modifiable factors that exacerbate or protect from age-related cognitive decline.
Could this study be right for you?
Eligibility Criteria:
- Aged 18 years and older
- Speak English
- History of concussion, traumatic brain injury, and/or posttraumatic stress disorder
- Must have primary care physician
Age Range
18 and up -
Perinatal Arterial Stroke: The I-ACQUIRE Study
Official Title Perinatal Arterial Stroke: The I-ACQUIRE StudyPurpose
Children who suffered a stroke before or shortly after being born that was caused by blockage of blood flow in an artery, it often results in the child showing some weakness on one side of their body.
With this study, we want to find out if a type of therapy may help children who have weakness on one side of their body due to perinatal arterial ischemic stroke, learn how to better use their weaker arm.
All children will be in the study for about 13 - 15 months. Some children may be in the study for a longer period, depending on which treatment they receive during Phase 1 of the study. The I-ACQUIRE therapy involves fun learning and play, self-help activities, and manipulating interesting toys and objects.
Could this study be right for you?
- Your child must be between the ages of 8 and 36 months old when beginning this study
- Your child must have suffered a perinatal arterial ischemic stroke
- Upper limb weakness
- Parents must be able to participate at least 1x/week for therapy and 40-60 minutes/day at home
-
A study on language impairment following a stroke
Official Title Laying the Groundwork for Personalized Medicine in Aphasia Therapy: Genetic and Cognitive Predictors of Restorative Treatment ResponsePurpose
This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.
Could this study be right for you?
Participants must meet the following criteria:
- Native English speaker
- Able to have an MRI
Age Range
18 and up -
MeSo Study
Official Title Mechanisms of Self and Other Evaluation (MeSO Study)Purpose
The purpose of this study is to better understand the way the brain works in people who have depression and people who have previously been depressed. We are also testing healthy subjects for comparison. We hope our findings will lead to better ways to diagnose and treat mood disorders in the future. Participation involves an initial phone call and a 2 to 4 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan. Two months after the scan, participants will complete daily online questionnaires for 7 days. This process is repeated 2 months later (4 months after the scan).
Could this study be right for you?
You may be eligible for this study if you:
- Are between the ages of 18-40
- Are right-handed
- Do not have a history of neurological disorders (e.g., seizures, head injury, etc.)
- Do not have major medical problems (e.g., stroke, heart disease, high blood pressure, endocrine disorders, etc.)
- Have normal vision, vision that is corrected to normal with glasses or contacts
- Are willing and able to undergo fMRI scanning (not claustrophobic, no non-removable metal in your body)
- Are not pregnant
Age Range
18 and up -
Cognition and Brain Circuitry
Official Title Cognition and Brain CircuitryPurpose
The purpose of the study is to look at how our brain networks interact for different mental functions and how individual differences in brain structure and function determines individual differences in behavior. During this study, we use magnetic resonance imaging methods: functional magnetic resonance imaging (fMRI) and diffusion weighted imaging (DWI). Functional MRI (fMRI) and DWI are typical imaging methods that use a strong magnetic field and radio waves to make pictures of your body. The total length of the study will be between 3 and 4 hours, including up to 2 hours outside the MRI scanner and 2 hours in the scanner.
Could this study be right for you?
- Healthy adults between 18-40 years of age
- Have normal or corrected-to-normal vision
Age Range
18 and up -
Vercise™ DBS Registry
Official Title Registry of Deep Brain Stimulation with the VERCISE™ System: Vercise™ DBS RegistryPurpose
The purpose of this study is to record the personal experiences of those who have had Deep Brain Stimulation (DBS) using the Vercise™ System, for the treatment of Parkinson's Disease.
Could this study be right for you?
You may be eligible if you are:
- At least 18 years of age
- Planning to receive the currently available Vercise™ System and/or any new commercially approved parts such as leads, extension, Adaptor, CP, etc. that works with the Vercise System
Age Range
18 and up -
Abbott DBS (Deep Brain Stimulation) Registry
Official Title ABT-CIP-10300: Abbott DBS Registry of Outcomes for Indications over Time (ADROIT)Purpose
The purpose of this study is to collect information and evaluate outcomes for Abbott Deep Brain Stimulation (DBS) systems that are approved and sold in your country.
In order to evaluate how the DBS system performs, data will be collected before, during and after DBS implant when you visit the study doctor. The data collected will include information on your movements, feelings, daily activities, and DBS program settings.
The information gathered in this study will add to the understanding of treatment options for future patients receiving DBS.
Could this study be right for you?
Inclusion Criteria:
- You are scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 3 months
Exclusion Criteria:
- You are currently enrolled or plan to enroll in another study that may alter the results of this clinical investigation
- You have another disease, conditions, or other medical, social, or psychological conditions that could limit your ability to participate in the clinical investigation or to satisfy follow-up requirements
-
A Study to Compare Medications in Patients with Advanced Parkinson's Disease
Official Title A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease PatientsPurpose
The purpose of this study is to find out how well ABBV-951 works to control Parkinson's disease symptoms compared to oral Carbidopa (CD)/Levodopa (LD). The study is also seeking to test whether ABBV-951 is well tolerated in patients with Parkinson's disease.
Could this study be right for you?
- Male or female, age 30 or older
- Has not received deep brain stimulation, Carbidopa (CD)/Levodopa (LD) enteral suspension, or any other Parkinson's Disease (PD) medication as continuous daily infusion
- Subject does not have a history of significant skin conditions or disorders
- Subject does not have a recent (within 6 months before screening) history of drug or alcohol abuse
- Subject does not have a history or presence of psychotic episodes
- Subject does not have other clinically significant unstable medical conditions
- Subject must have a diagnosis of levodopa-responsive idiopathic PD
* other eligibility criteria to be discussed/reviewed with the study team
Age Range
30 and up